Your session is about to expire
← Back to Search
Rucaparib + Enzalutamide for Prostate Cancer (CASPAR Trial)
CASPAR Trial Summary
This trial is testing if a combination of two drugs, rucaparib and enzalutamide, is better than enzalutamide alone for treating men with prostate cancer that has spread and become resistant to testosterone-deprivation therapy.
CASPAR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCASPAR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CASPAR Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is Rucaparib camsylate a safe prescription medication?
"3."
In how many different medical facilities is this research project being conducted currently?
"There are 100 patients enrolling in this clinical trial at the West Michigan Cancer Center in Kalamazoo, Saint Joseph Mercy Brighton in Brighton, and Spectrum Health at Butterworth Campus in Grand Rapids. There are also 100 other enrollees spread out across different locations."
What is the main therapeutic purpose of Rucaparib camsylate?
"While Rucaparib camsylate is most frequently used to treat breast cancer, it can also help patients manage side effects of radiation therapy and endometrial thinning. It is even effective against stage t2b carcinoma of the prostate."
Can patients sign up for this clinical trial at this time?
"That is correct, based on the information available clinicaltrials.gov this study is looking for 1002 patients at 100 different locations and is still actively recruiting as of 9/25/2022."
How many people have been signed up to participate in this clinical trial?
"That is accurate, the clinicaltrials.gov website shows that this trial is open and looking for candidates. The listing appeared on 2/19/2021 and was updated as recently as 9/25/2022. They are hoping to 1002 people across 100 different locations."
Have other similar trials been conducted in the past?
"Rucaparib camsylate has been researched since 2000 when it was first trialed by AstraZeneca. The Phase 3 drug approval happened in light of the successful 600 person study. Today, there are 245 active studies involving Rucaparib camsylate being conducted across 63 countries and 2316 cities"
What goals does this research aim to achieve?
"The aim of this study, which will be conducted over a period of up to 5 years after treatment, is to assess overall survival rates. Secondary outcomes include the incidence of adverse events as measured by the National Cancer Institute's Common Toxicity Criteria, prostate specific antigen (PSA) response rates, and radiographic progression-free survival within HRRm status. Treatment arm comparisons will be made using chi-square tests and log-rank tests, with median times per treatment arm being reported."
What similar investigations has Rucaparib camsylate been a part of in the past?
"Rucaparib camsylate is being studied in 245 different clinical trials. Of those, 71 are Phase 3 trials. Many of the studies related to Rucaparib camsylate originate from Lincoln, Nebraska; however, there are 14809 total locations running these medical trials."
Share this study with friends
Copy Link
Messenger